Overview
Dr. Rohan Ramakrishna is an award-winning neurosurgeon who specializes in the treatment of brain tumors and other central nervous system tumors. Dr. Ramakrishna treats patients with gliomas, metastatic disease, skull base lesions, and pituitary disorders. He employs advanced awake mapping, imaging techniques, and microsurgery to ensure maximal tumor removal and achieve the safest possible surgical outcomes. Furthermore, Dr. Ramakrishna works with a multi-disciplinary team to ensure that the best possible treatment strategies are offered to his patients. He sees patients at the Brain Tumor Center at New York Presbyterian/Weill Cornell Medical Center as part of the surgical neuro-oncology team.
Training
Dr. Ramakrishna received his Bachelor of Arts from the University of Pennsylvania, majoring in Biology and Philosophy, and was elected to the Phi Beta Kappa society upon graduation. He obtained his medical degree from the University of Pennsylvania. Dr. Ramakrishna completed his neurosurgery residency and served as chief resident at the University of Washington. He then went on to complete a fellowship in neurosurgical oncology at the MD Anderson Cancer Center in Houston, Texas.
Research
Dr. Ramakrishna’s research interests include novel drug delivery strategies to treat malignant brain and skull base tumors using advanced polymer and nanoparticle technology. Additionally, Dr. Ramakrishna is interested in developing new vaccine-based therapies for glioma and in helping to develop new clinical trials and outcome measures to advance the care of brain tumors. He has published and spoken extensively on these topics and has received multiple awards, including prestigious training and research grants from the NIH and the Fred Hutchinson Cancer Consortium.
Highlights
- 1
- 2Acta neurochirurgica · 2023
- 3
Publications
Funding
Active
2 grants- Co-IR01CA308323-01A1Dual-[Hypoxia+Proliferation] PET as a Predictive Biomarker in Recurrent GlioblastomaNational Cancer Institute · 2026–2031
- Co-IR21CA289111-01A1Somatostatin Receptor 2 Expression in Pituitary Neuroendocrine Tumors as a Basis for PET/MRI guided Subtype Stratification and Radiotherapy PlanningNational Cancer Institute · 2025–2027
Completed grants (5)
- Sub-PIR01CA246503-05Influence of pre-analytical factors in glioblastoma MGMT promoter methylation biomarker assayNational Cancer Institute · 2024–2025 · via University of Washington, TheNo publications yet
- Co-INYPH 203205-02Deciphering cellular hierarchies and plasticity in diffuse gliomas by single-cell multi-omics (Competitive Renewal)William Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2020–2022
- Co-IWRCG 210432-01Machine Learning Approaches to Improve Histological Interpretation of GlioblastomaWilliam Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2020–2021
- PIWCMC 200781-01Machine Learning Approaches to Central Nervous System Tumor Diagnostics Using Multi-parametric, Heterogeneous Input Data SetsWeill Cornell Medical College · 2019–2020
- KPNYPH 15050722-02Improving Quality: Outcomes and Patient SatisfactionNew York State Department of Health · 2015–2017 · via New York Presbyterian Hospital
Clinical research
Active
4 studies- PINCT05902169A Randomized, Open-label, Multicentric, Two-arm Pivotal Trial of SonoCloud-9 Combined With Carboplatin (CBDCA) vs Standard of Care Lomustine (CCNU) or Temozolomide (TMZ) in Patients Undergoing Planned Resection for First Recurrence Glioblastoma.PHASE3 · Carthera SaS · OPEN TO ACCRUAL (as of 2026)Glioblastoma; Recurrent Glioblastoma; GBM
- PIDemographics and Clinical Outcomes as a Function or Zipcode of Neurosurgical Patients Undergoing Oncological ProceduresWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
- PIAssessing Genomic and Cell Culture Differences in Glioblastoma A Pilot StudyWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2020)
- PIGenetic, Epigenetic, and Phenotypic Heterogeneity in Human Brain ComponentsWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2020)
Completed & closed trials (1)
- PINCT04485949A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With GlioblastomaPHASE2 · Imvax, Inc. · CLOSED TO ACCRUAL (as of 2024)Glioblastoma
External relationships
Ownership
Carespace Health
Professional Services
Carespace Health
Other
Carespace Health